Skip to main content

Advertisement

SpringerLink
Log in

Association of IL-10 polymorphisms with prostate cancer risk and grade of disease

  • Original Paper
  • Published:
Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Animal and in vitro models of prostate cancer demonstrate high IL-10 levels result in smaller tumors, fewer metastases, and reduced angiogenesis compared to controls. We sought to examine the hypothesis that genotypes correlated with low IL-10 production may be associated with increased prostate cancer risk among Finnish male participants from the Alpha-tocopherol Beta-carotene Cancer Prevention Study. DNA from 584 prostate cancer cases and 584 controls was genotyped for four IL-10 alleles, −1082, −819, −592, and 210. DNA from more of the controls than cases failed to amplify, resulting in 509 cases and 382 controls with genotype data for −1082; 507 and 384 for −819; 511 and 386 for −592; and 491 and 362 for 210. Odds ratios for the association between the IL-10 genotypes and risk of prostate cancer or, among cases only, high-grade disease were calculated using logistic regression. In this population, the −819 TT and −592 AA low expression genotypes were highly correlated. These two genotypes also were associated with increased prostate cancer susceptibility (OR = 1.92, 95% CI 1.07–3.43 for −819) and, among cases, with high-grade tumors (OR = 2.56, 95% CI 1.26–5.20 for −819). These data demonstrate genotypes correlated with low IL-10 production are associated with increased risk of prostate cancer and with high-grade disease in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M (1996) Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2:1969–1979

    PubMed  CAS  Google Scholar 

  2. Stearns ME, Fudge K, Garcia F, Wang M (1997) IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17:62–74

    PubMed  CAS  Google Scholar 

  3. Stearns ME, Wang M (1998) Antimetastatic and antitumor activities of interleukin 10 in transfected human prostate PC-3 ML clones: orthotopic growth in severe combined immunodeficient mice. Clin Cancer Res 4:2257–2263

    PubMed  CAS  Google Scholar 

  4. Stearns ME, Rhim J, Wang M (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5:189–196

    PubMed  CAS  Google Scholar 

  5. Howell WM, Rose-Zerilli MJ (2006) Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5:143–149

    Article  PubMed  CAS  Google Scholar 

  6. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH et al (2000) Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231:552–558

    Article  PubMed  CAS  Google Scholar 

  7. Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L et al (2004) Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol 22:4575–4583

    Article  PubMed  Google Scholar 

  8. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D (2001) Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19:239–247

    Article  PubMed  CAS  Google Scholar 

  9. Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164:722–725

    Article  PubMed  CAS  Google Scholar 

  10. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE (1999) Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 30:526–530

    Article  PubMed  CAS  Google Scholar 

  11. Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH et al (2003) Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 12:901–906

    Article  PubMed  CAS  Google Scholar 

  12. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C (2003) Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75:711–717

    Article  PubMed  CAS  Google Scholar 

  13. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8

    PubMed  CAS  Google Scholar 

  14. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372

    PubMed  CAS  Google Scholar 

  15. Eder T, Mayer R, Langsenlehner U, Renner W, Krippl P, Wascher TC et al (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 43:472–475

    Article  PubMed  CAS  Google Scholar 

  16. Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC et al (2005) The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14:2563–2568

    Article  PubMed  CAS  Google Scholar 

  17. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED et al (2006) Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 66:4525–4530

    Article  PubMed  CAS  Google Scholar 

  18. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035

    Article  Google Scholar 

  19. The ATBC Cancer Prevention Study Group (1994) The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 4:1–10

    Article  Google Scholar 

  20. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM et al (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90:440–446

    Article  PubMed  CAS  Google Scholar 

  21. Woodson K, Ratnasinghe D, Bhat NK, Stewart C, Tangrea JA, Hartman TJ et al (1999) Prevalence of disease-related DNA polymorphisms among participants in a large cancer prevention trial. Eur J Cancer Prev 8:441–447

    Article  PubMed  CAS  Google Scholar 

  22. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P (2005) A haplotype map of the human genome. Nature 437:1299–1320

    Article  CAS  Google Scholar 

  23. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O’Brien SJ et al (2003) Non-Hodgkin’s B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 109:119–129

    Article  PubMed  CAS  Google Scholar 

  24. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ et al (2000) Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 97:14467–14472

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported in part by the intramural research program of the Center for Cancer Research, National Cancer Institute, Bethesda, MD. The ATBC Study was supported by Public Health Services contract N01-CN-45165, N01-RC-45035, and N01-RC-37004 from the National Cancer Institute, Bethesda, MD.

Author information

Authors and Affiliations

  1. Cancer Prevention Fellowship Program, Division of Cancer Prevention and Mammary Biology and Tumorigenesis Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 1106, Bethesda, MD, 20892-4254, USA

    Jessica M. Faupel-Badger

  2. Cancer Prevention & Control Program, Department of Pharmacology & Toxicology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Louisville, KY, USA

    La Creis Renee Kidd

  3. Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Demetrius Albanes

  4. Department of Health Promotion and Chronic Disease Prevention, National Public Health Institute, Helsinki, Finland

    Jarmo Virtamo

  5. Cancer Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Karen Woodson

  6. Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Joseph A. Tangrea

Authors
  1. Jessica M. Faupel-Badger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. La Creis Renee Kidd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Demetrius Albanes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jarmo Virtamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karen Woodson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joseph A. Tangrea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica M. Faupel-Badger.

Additional information

The U.S. Government’s right to retain a non-exclusive, royalty-free license in and to any copyright is acknowledged.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Faupel-Badger, J.M., Kidd, L.C.R., Albanes, D. et al. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19, 119–124 (2008). https://doi.org/10.1007/s10552-007-9077-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-007-9077-6

Keywords

Search

Navigation